Vivos Therapeutics Reduces Debt Through Strategic Equity Exchange Agreement
Vivos Therapeutics (NASDAQ: VVOS) announced a binding agreement with its senior secured lender, Streeterville Capital LLC, to exchange up to $4.5 million of outstanding debt into a combination of perpetual non-convertible preferred stock and common shares. The transaction is designed to strengthen the company’s balance sheet and support its long-term growth strategy.
The agreement also includes commitments from Streeterville to suspend repayment demands and temporarily refrain from selling company securities following the debt-to-equity exchange. Vivos is a healthcare and medical device company focused on treating breathing-related sleep disorders, including obstructive sleep apnea, and associated chronic health conditions.
#VivosTherapeutics
#VVOS
#SleepApnea
#Healthcare
#MedicalDevices
#HealthTech
#Biotech
#DebtRestructuring
#Nasdaq
#CorporateFinance
#ObstructiveSleepApnea
#HealthcareInnovation
#InvestorNews
#JaneKing
#NewsOut
